Stenting for symptomatic intracranial arterial stenosis in China: 1-year outcome of a multicentre registry study

Ning Ma, Yong Zhang, Jie Shuai, Changchun Jiang, Qiyi Zhu, Kangning Chen, Li Liu, Baomin Li, Xiangqun Shi, Lianbo Gao, Yajie Liu, Feng Wang, Yongli Li, Tieyan Liu, Hongbo Zheng, Dapeng Mo, Feng Gao, Yilong Wang, Yongjun Wang, Lei Feng, Zhongrong Miao, Ning Ma, Yong Zhang, Jie Shuai, Changchun Jiang, Qiyi Zhu, Kangning Chen, Li Liu, Baomin Li, Xiangqun Shi, Lianbo Gao, Yajie Liu, Feng Wang, Yongli Li, Tieyan Liu, Hongbo Zheng, Dapeng Mo, Feng Gao, Yilong Wang, Yongjun Wang, Lei Feng, Zhongrong Miao

Abstract

Background and purpose: A multicentre prospective registry study of individually tailored stenting for a patient with symptomatic intracranial atherosclerotic stenosis (ICAS) combined with poor collaterals in China showed that the short-term safety and efficacy of stenting was acceptable. However, it remained uncertain whether the low event rate could be of a long term. We reported the 1-year outcome of this registry study to evaluate the long-term efficacy of individually tailored stenting for patients with severe symptomatic ICAS combined with poor collaterals.

Methods: Patients with symptomatic ICAS caused by 70%-99% stenosis located at the intracranial internal carotid, middle cerebral, intracranial vertebral or basilar arteries combined with poor collaterals were enrolled. Balloon-mounted stent or balloon plus self-expanding stent were selected based on the ease of vascular access and lesion morphology determined by the operators. The primary outcome was the rate of 30-day stroke, transient ischaemic attack and death, and 12-month ischaemic stroke within the same vascular territory, haemorrhagic stroke and vascular death after stenting.

Results: From September 2013 to January 2015, 300 patients (ages 58.3±9.78 years) were recruited. Among them, 159 patients were treated with balloon-mounted stent and 141 with balloon plus self-expanding stent. During the 1-year follow-up, 25 patients had a primary end point event. The probability of primary outcome at 1 year was 8.1% (95% CI 5.3% to 11.7%). In 76 patients with digital subtraction angiography follow-up, 27.6% (21/76) had re-stenosis ≥50% and 18.4% (14/76) had re-stenosis ≥70%. No baseline characteristic was associated with the primary outcome.

Conclusion: The event rate remains low over 1 year of individually tailored stenting for patients with severe symptomatic ICAS combined with poor collaterals. Further randomised trial of comparing individually tailored stenting with best medical therapy is needed.

Trial registration number: NCT01968122; Results.

Keywords: angioplasty and stenting; atherosclerosis; intracranial stenosis.

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow chart of participants.
Figure 2
Figure 2
A 66-year-old male patient with symptomatic left intracranial carotid artery stenosis treated with balloon-mounted stenting. (A) CT angiography showed severe left intracranial atherosclerotic stenosis. (B) CT perfusion showed obvious hypoperfusion of the left hemisphere compared with that of the right hemishphere. (C) The lesion was treated with a balloon-mounted stent (2.5 mm × 8 mm). The degree of stenosis decreased from 85% to 0%. CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time; TTP, time to peak.
Figure 3
Figure 3
A 44-year-old male patient with symptomatic left intracranial vertebral artery stenosis treated with balloon predilation plus self-expanding stenting. (A) CT angiography showed a severe left intracranial vertebral artery stenosis. (B) CT perfusion showed hypoperfusion in the posterior circulation territory compared with that in the anterior circulation territory. (C) The lesion was treated with a balloon (2.5 mm × 15 mm) and then implantation of a self-expanding stent (3.0 mm × 20 mm). The degree of stenosis decreased from 90% to 0%. CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time; TTP, time to peak.
Figure 4
Figure 4
Cumulative probability of a primary outcome.

References

    1. Redon J, Olsen MH, Cooper RS, et al. . Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011;32:1424–31. 10.1093/eurheartj/ehr045
    1. Wong KS, Li H, Lam WW, et al. . Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke 2002;33:532–6. 10.1161/hs0202.102602
    1. Zaidat OO, Klucznik R, Alexander MJ, et al. . The NIH registry on use of the wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008;70:1518–24. 10.1212/01.wnl.0000306308.08229.a3
    1. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. . Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003. 10.1056/NEJMoa1105335
    1. Zaidat OO, Fitzsimmons BF, Woodward BK, et al. . Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015;313:1240–8. 10.1001/jama.2015.1693
    1. Derdeyn CP, Chimowitz MI, Lynn MJ, et al. . Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 2014;383:333–41. 10.1016/S0140-6736(13)62038-3
    1. Liebeskind DS, Cotsonis GA, Saver JL, et al. . Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Investigators. Collaterals dramatically alter stroke risk in intracranial atherosclerosis. Ann Neurol 2011;69:963–74.
    1. Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res 2017;120:502–13. 10.1161/CIRCRESAHA.116.308441
    1. Jiang WJ, Yu W, Du B, et al. . Outcome of patients with ≥70% symptomatic intracranial stenosis after Wingspan stenting. Stroke 2011;42:1971–5. 10.1161/STROKEAHA.110.595926
    1. Jiang WJ, Xu XT, Jin M, et al. . Apollo stent for symptomatic atherosclerotic intracranial stenosis: study results. AJNR Am J Neuroradiol 2007;28:830–4.
    1. Miao Z, Song L, Liebeskind DS, et al. . Outcomes of tailored angioplasty and/or stenting for symptomatic intracranial atherosclerosis: a prospective cohort study after SAMMPRIS. J Neurointerv Surg 2015;7:331–5. 10.1136/neurintsurg-2014-011109
    1. Miao Z. Intracranial angioplasty and stenting before and after SAMMPRIS: "from simple to complex strategy - the chinese experience". Front Neurol 2014;5:129 10.3389/fneur.2014.00129
    1. Wang Y, Miao Z, Wang Y, et al. . Protocol for a prospective, multicentre registry study of stenting for symptomatic intracranial artery stenosis in China. BMJ Open 2014;4:e005175 10.1136/bmjopen-2014-005175
    1. Miao Z, Zhang Y, Shuai J, et al. . Thirty-Day Outcome of a Multicenter Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China. Stroke 2015;46:2822–9. 10.1161/STROKEAHA.115.010549
    1. Samuels OB, Joseph GJ, Lynn MJ, et al. . A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:643–6.
    1. Higashida R, Furlan A, Roberts H, et al. . Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol 2003;14:E1–E31. 10.1016/S1051-0443(07)60431-X
    1. Shuaib A, Butcher K, Mohammad AA, et al. . Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 2011;10:909–21. 10.1016/S1474-4422(11)70195-8
    1. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol 2013;12:1106–14. 10.1016/S1474-4422(13)70195-9
    1. Mori T, Fukuoka M, Kazita K, et al. . Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol 1998;19:1525–33.
    1. Turan TN, Nizam A, Lynn MJ, et al. . Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology 2017;88:379–85. 10.1212/WNL.0000000000003534
    1. Lutsep HL, Lynn MJ, Cotsonis GA, et al. . Does the stenting versus aggressive medical therapy trial support stenting for subgroups with intracranial stenosis? Stroke 2015;46:3282–4. 10.1161/STROKEAHA.115.009846
    1. Gröschel K, Schnaudigel S, Pilgram SM, et al. . A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009;40:e340–e347. 10.1161/STROKEAHA.108.532713
    1. Jin M, Fu X, Wei Y, et al. . Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis. Stroke 2013;44:2990–4. 10.1161/STROKEAHA.113.001824

Source: PubMed

3
Abonnere